Critical Survey: Bioqual (OTCMKTS:BIOQ) versus Daxor (NASDAQ:DXR)

Daxor (NASDAQ:DXR) and Bioqual (OTCMKTS:BIOQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Daxor and Bioqual, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	1	1	0	2.50
Bioqual	0	0	0	0	0.00

Daxor currently has a consensus price target of $25.00, suggesting a potential upside of 84.64%. Given Daxor’s stronger consensus rating and higher probable upside, analysts plainly believe Daxor is more favorable than Bioqual.

Profitability

This table compares Daxor and Bioqual’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Bioqual	-2.14%	-2.90%	-1.87%

Volatility & Risk

Daxor has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.

Institutional & Insider Ownership

1.3% of Daxor shares are owned by institutional investors. 59.5% of Daxor shares are owned by insiders. Comparatively, 39.2% of Bioqual shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Daxor and Bioqual”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Bioqual	$48.87 million	0.73	-$1.05 million	($1.18)	-33.90

Daxor has higher earnings, but lower revenue than Bioqual.

Summary

Daxor beats Bioqual on 9 of the 10 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.